Literature DB >> 24107973

Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation.

Gyeong-Won Lee1, Sung Yong Oh, Myoung Hee Kang, Jung Hun Kang, Se Hoon Park, In Gyu Hwang, Seong Yoon Yi, Young Jin Choi, Jun Ho Ji, Ha Yeon Lee, Eduardo Bruera.   

Abstract

Dexamethasone-induced hiccup (DIH) is an underrecognized symptom in patients with cancer, and little information is available about its treatment. The aims of this study were to investigate the feasibility of methylprednisolone rotation as treatment and to confirm the male predominance among those with cancer who experienced DIH during chemotherapy. Methods. Persons with cancer who experienced hiccups during chemotherapy treatment and who were receiving treatment with dexamethasone were presumed to have DIH. The following algorithmic practice was implemented for antiemetic corticosteroid use: rotation from dexamethasone to methylprednisolone in the next cycle and dexamethasone re-administration in the second cycle of chemotherapy after recognition of hiccups to confirm DIH. All other antiemetics except corticosteroid remained unchanged. Patients (n = 40) were recruited from eight cancer centers in Korea from September 2012 to April 2013. Data were collected retrospectively. Results. Hiccup intensity (numeric rating scale [NRS]: 5.38 vs. 0.53) and duration (68.44 minutes vs. 1.79 minutes) were significantly decreased after rotation to methylprednisolone, while intensity of emesis was not increased (NRS: 2.63 vs. 2.08). Median dose of dexamethasone and methylprednisolone were 10 mg and 50 mg, respectively. Thirty-four (85%) of 40 patients showed complete resolution of hiccups after methylprednisolone rotation in the next cycle. Of these 34 patients, 25 (73.5%) had recurrence of hiccups after dexamethasone re-administration. Compared with baseline values, hiccup intensity (NRS: 5.24 vs. 2.44) and duration (66.43 minutes vs. 22.00 minutes) were significantly attenuated after dexamethasone re-administration. Of the 40 eligible patients, 38 (95%) were male. Conclusion. DIH during chemotherapy could be controlled without losing antiemetic potential by replacing dexamethasone with methylprednisolone. We also identified a male predominance of DIH. Further prospective studies are warranted.

Entities:  

Keywords:  Corticosteroids; Dexamethasone; Hiccup; Methylprednisolone

Mesh:

Substances:

Year:  2013        PMID: 24107973      PMCID: PMC3825309          DOI: 10.1634/theoncologist.2013-0224

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  23 in total

1.  Hiccups as an adverse reaction to cancer chemotherapy.

Authors:  Yuichi Takiguchi; Reiko Watanabe; Keiichi Nagao; Takayuki Kuriyama
Journal:  J Natl Cancer Inst       Date:  2002-05-15       Impact factor: 13.506

Review 2.  Treatment of chronic hiccups in cancer patients: a systematic review.

Authors:  Agnès Calsina-Berna; Garbiñe García-Gómez; Jesús González-Barboteo; Josep Porta-Sales
Journal:  J Palliat Med       Date:  2012-08-14       Impact factor: 2.947

3.  Sex differences in corticosteroid binding in the rat brain: an in vitro autoradiographic study.

Authors:  N J MacLusky; H Yuan; J Elliott; T J Brown
Journal:  Brain Res       Date:  1996-02-05       Impact factor: 3.252

4.  An experimental study of hiccup.

Authors:  J N Davis
Journal:  Brain       Date:  1970       Impact factor: 13.501

5.  Sex differences in type I corticosteroid receptor binding in selective brain areas of rats.

Authors:  C M McCormick; J W Smythe; D Beers
Journal:  Ann N Y Acad Sci       Date:  1994-11-30       Impact factor: 5.691

6.  The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients.

Authors:  E Bruera; N Kuehn; M J Miller; P Selmser; K Macmillan
Journal:  J Palliat Care       Date:  1991       Impact factor: 2.250

7.  Sexual dimorphism of glucocorticoid binding in rat brain.

Authors:  B B Turner; D A Weaver
Journal:  Brain Res       Date:  1985-09-16       Impact factor: 3.252

8.  Methylprednisolone in cis-platinum induced nausea and emesis: a placebo-controlled trial.

Authors:  C A Metz; R S Freedman; J F Magrina
Journal:  Gynecol Oncol       Date:  1987-05       Impact factor: 5.482

9.  Improved control of cisplatin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial.

Authors:  Y Bécouarn; B B Nguyen; M David; F Lakdja; R Brunet; J Chauvergne
Journal:  Eur J Cancer Clin Oncol       Date:  1986-12

10.  Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.

Authors:  B Chevallier; M Marty; J M Paillarse
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more
  6 in total

1.  Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial.

Authors:  Se-Il Go; Dong-Hoe Koo; Seung Tae Kim; Haa-Na Song; Rock Bum Kim; Joung-Soon Jang; Sung Yong Oh; Kyung Hee Lee; Soon Il Lee; Seong-Geun Kim; Lee Chun Park; Sang-Cheol Lee; Byeong-Bae Park; Jun Ho Ji; Seong Yoon Yi; Yun-Gyoo Lee; Jina Yun; Eduardo Bruera; In Gyu Hwang; Jung Hun Kang
Journal:  Oncologist       Date:  2017-07-07

2.  Association of hiccup and SARS-CoV-2 infection with the administration of dexamethasone: a case report.

Authors:  Victoria Bîrluţiu; Ciprian Radu Şofariu
Journal:  Germs       Date:  2022-03-31

3.  Hiccups in patients with cancer: a multi-site, single-institution study of etiology, severity, complications, interventions, and outcomes.

Authors:  Christopher J Ehret; Yahya Almodallal; Jennifer G Le-Rademacher; Nichole A Martin; Michael R Moynagh; Arush Rajotia; Aminah Jatoi
Journal:  BMC Cancer       Date:  2022-06-15       Impact factor: 4.638

Review 4.  Do Patients Benefit from a Trial of Corticosteroids at the End of Life?

Authors:  Sriram Yennurajalingam; Eduardo Bruera
Journal:  Curr Treat Options Oncol       Date:  2022-04-01

5.  Analysis of factors associated with hiccups based on the Japanese Adverse Drug Event Report database.

Authors:  Ryuichiro Hosoya; Yoshihiro Uesawa; Reiko Ishii-Nozawa; Hajime Kagaya
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

6.  Analysis of Factors Associated with Hiccups Using the FAERS Database.

Authors:  Ryuichiro Hosoya; Reiko Ishii-Nozawa; Kota Kurosaki; Yoshihiro Uesawa
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.